Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands |
| |
| Institution: | 1. Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands;2. Institute for Medical Technology Assessment, Erasmus University, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands;3. Department of Medical Oncology, VU University Medical Centre, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands;4. Department of Medical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands;5. Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands;6. Department of Internal Medicine, Zuyderland Medical Centre Heerlen-Sittard, Henri Dunantstraat 5, 6419 PC, Heerlen, The Netherlands;7. Department of Pathology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands;8. Netherlands Comprehensive Cancer Organisation, Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands;9. Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, 3582, CX, Utrecht, The Netherlands;10. Department of Medical Oncology, Isala, Dokter van Heesweg 2, 8025 AB, Zwolle, The Netherlands;11. Department of Medical Oncology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands;12. Department of Medical Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands;13. Department of Medical Oncology, Erasmus MC Cancer Institute, ''s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands;14. Department of Internal Medicine, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands;15. Department of Internal Medicine, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands;p. Department of Internal Medicine, Amphia Hospital, Molengracht 21, 4818 CK, Breda, The Netherlands;q. Department of Internal Medicine, Maxima Medical Centre, De Run 4600, 5504 DB, Eindhoven, The Netherlands;r. Department of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands;1. Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA;2. Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, 33612, USA;3. Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, 33612, USA;1. Scientific Bureau, Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, Leiden 2333AA, the Netherlands;2. Department of Medical Oncology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584CX, the Netherlands;3. Department of Pathology, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht 3584CX, the Netherlands;4. Department of Biomedical Data Sciences, Leiden University Medical Centre, Einthovenweg 20, Leiden 2333ZC, the Netherlands;5. Department of Surgical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066CX, the Netherlands;1. Department of Dermatology, University Hospital Essen, Essen, Germany;2. Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany;3. Department of Oncology Hornheide, Fachklinik Hornheide, Münster, Germany;4. Department of Dermatology, University Hospital Tübingen, Tübingen, Germany;5. Department of Dermatology, University Hospital Mainz, Mainz, Germany;6. Department of Dermatology, University Hospital Regensburg, Regensburg, Germany;7. Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany;8. Department of Dermatology, University Hospital Dresden, Dresden, Germany;9. Department of Dermatology, Elbe-Kliniken, Buxtehude, Germany;10. Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;11. Department of Dermatology, University Hospital Würzburg, Würzburg, Germany;12. Department of Dermatology, Charité Campus Mitte, Berlin, Germany;13. Department of Dermatology, Ludwigshafen Medical Center, Ludwigshafen, Germany;14. German Cancer Research Center (DKFZ), Heidelberg, Germany;15. Department of Dermatology, Leipzig University Hospital Medical Center, Leipzig, Germany;p. Alcedis GmbH, Giessen, Germany;q. Translational Skin Cancer Research, German Cancer Consortium (DKTK), Partner Site Essen, Medical Faculty, University of Duisburg-Essen, Essen, Germany;r. German Cancer Consortium (DKTK), University of Duisburg-Essen, Essen, Germany;1. Guy''s & St Thomas'' Hospitals NHS Foundation Trust, London, UK;2. Servicio de Dermatología, Hospital Clínic de Barcelona, Catalonia, Spain;3. Assistance Publique – Hôpitaux de Paris (AP-HP) Hôpital Saint-Louis, Dermatology Department Université Paris-Diderot, Sorbonne Paris Cité, INSERM UMR-S 976, Paris, France;4. Adelphi Values, Bollington, UK;5. Amgen Ltd., Uxbridge, London UK;6. Amgen GmbH, Zug, Switzerland;7. Klinik für Dermatologie, Universitätsklinikum Essen, Essen, Germany;1. Dept. of Dermatology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Germany;2. Dept. of Dermatology, National Center for Tumor Diseases, University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany;3. Dept. of Dermatology, University of Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany;4. Dept. of Dermatology and Allergology, University Hospital, LMU Munich, Frauenlobstraße 9–11, 80337 Munich, Germany;5. Dept. of Dermatology, Venerology and Allergology, University Medical Center Mainz, Germany;6. Dept. of Dermatology, Venerology and Allergology, University Hospital Freiburg, Germany;7. Dept. of Dermatology, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Germany;8. Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany;9. Dept. of Dermatology, University Hospital Regensburg, Germany;10. Skin Cancer Center at the University Cancer Centre Dresden, National Center for Tumor Diseases, Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany;11. Dept. of Dermatology, Venerology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Germany;12. Dept. of Dermatology, University Hospital Münster, Von Esmarch Str. 58, 48149, Münster, Germany;13. Dept. of Dermatology, Venerology and Allergology, University Hospital Erlangen, Germany;14. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA;15. The Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai, New York, NY, 10029, USA;p. Dept. of Dermatology, University Medical Center Goettingen Goettingen, Germany;q. Clinic for Dermatology, Venerology and Allergology, Havelklinik Berlin, Germany;r. Saarland University Medical School, Department of Dermatology, Homburg, Saar, Germany;s. Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Dermatology, Venerology and Allergology, Berlin, Germany;t. Rudolf-Schönheimer-Institute of Biochemistry, Medical Faculty of the University Leipzig, Johannisallee 30, 04103, Leipzig, Germany;u. German Cancer Consortium (DKTK), Heidelberg, Germany;v. Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 58167, Mannheim, Germany;1. Gustave Roussy Cancer Campus Grand Paris, Villejuif, France;2. Universite Paris-Sud, Kremlin-Bicêtre, France;3. University Hospital Zürich, Department of Dermatology, Zürich, Switzerland |
| |
| Abstract: | BackgroundIn recent years, the treatment of metastatic melanoma has changed dramatically due to the development of immune checkpoint and mitogen-activated protein (MAP) kinase inhibitors. A population-based registry, the Dutch Melanoma Treatment Registry (DMTR), was set up in July 2013 to assure the safety and quality of melanoma care in the Netherlands. This article describes the design and objectives of the DMTR and presents some results of the first 2 years of registration.MethodsThe DMTR documents detailed information on all Dutch patients with unresectable stage IIIc or IV melanoma. This includes tumour and patient characteristics, treatment patterns, clinical outcomes, quality of life, healthcare utilisation, informal care and productivity losses. These data are used for clinical auditing, increasing the transparency of melanoma care, providing insights into real-world cost-effectiveness and creating a platform for research.ResultsWithin 1 year, all melanoma centres were participating in the DMTR. The quality performance indicators demonstrated that the BRAF inhibitors and ipilimumab have been safely introduced in the Netherlands with toxicity rates that were consistent with the phase III trials conducted. The median overall survival of patients treated with systemic therapy was 10.1 months (95% confidence interval CI] 9.1–11.1) in the first registration year and 12.7 months (95% CI 11.6–13.7) in the second year.ConclusionThe DMTR is the first comprehensive multipurpose nationwide registry and its collaboration with all stakeholders involved in melanoma care reflects an integrative view of cancer management. In future, the DMTR will provide insights into challenging questions regarding the definition of possible subsets of patients who benefit most from the new drugs. |
| |
| Keywords: | Quality assurance Metastatic melanoma Checkpoint inhibitors MAP kinase inhibitors Population-based Registry Ipilimumab |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
